Judit Grueso Selected Research

Fulvestrant (Faslodex)

1/2020	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
4/2015	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Judit Grueso Research Topics

Disease

13	Neoplasms (Cancer) 01/2022 - 04/2010
10	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2012
2	Melanoma (Melanoma, Malignant) 06/2010 - 04/2010
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022
1	Ovarian Neoplasms (Ovarian Cancer) 01/2022
1	Disease Progression 01/2021
1	Inflammation (Inflammations) 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 12/2015
1	Skin Neoplasms (Skin Cancer) 10/2014
1	Peutz-Jeghers Syndrome (Polyposis, Hamartomatous Intestinal) 10/2014
1	Li-Fraumeni Syndrome 11/2013
1	Carcinoma (Carcinomatosis) 11/2013
1	Circulating Neoplastic Cells 11/2013
1	Triple Negative Breast Neoplasms 11/2012

Drug/Important Bio-Agent (IBA)

3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 11/2012
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2010
3	Estrogen ReceptorsIBA 01/2020 - 04/2015
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2016
2	Phosphotransferases (Kinase)IBA 01/2020 - 01/2016
2	Fulvestrant (Faslodex)FDA Link 01/2020 - 04/2015
2	olaparibIBA 12/2018 - 11/2012
2	Pharmaceutical PreparationsIBA 01/2016 - 06/2010
2	Cytostatic AgentsIBA 01/2016 - 06/2010
2	Mechanistic Target of Rapamycin Complex 1IBA 12/2015 - 05/2012
2	Lapatinib (GW572016)FDA Link 11/2013 - 05/2012
1	Messenger RNA (mRNA)IBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	PlatinumIBA 01/2022
1	Phenobarbital (Luminal)FDA Link 01/2022
1	AnthracyclinesIBA 01/2021
1	eribulin FDA Link 01/2021
1	taxaneIBA 01/2021
1	capivasertibIBA 01/2020
1	CytokinesIBA 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2020
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2018
1	Drug CombinationsIBA 01/2016
1	CyclinsIBA 01/2016
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2015
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 04/2015
1	Hormones (Hormone)IBA 04/2015
1	AlpelisibIBA 04/2015
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 10/2014
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2014
1	DNA (Deoxyribonucleic Acid)IBA 11/2012
1	NVP-BKM120IBA 11/2012
1	Trastuzumab (Herceptin)FDA Link 05/2012
1	Pemetrexed (MTA)FDA Link 06/2010
1	Cyclin D1IBA 06/2010
1	Ribosomal Proteins (Ribosomal Protein)IBA 06/2010
1	Sorafenib (BAY 43-9006)FDA Link 04/2010
1	PI103IBA 04/2010

Therapy/Procedure

8	Therapeutics 01/2022 - 05/2012
1	Precision Medicine 01/2020
1	Aftercare (After-Treatment) 05/2012